Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-HSA
- Development stage
- Preclinical
- Lead developer
- Ulm University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
89Zr-DFO-HSA is a preclinical positron emission tomography (PET) imaging radiopharmaceutical developed by researchers at Ulm University. It consists of human serum albumin (HSA) conjugated to the hexadentate chelator deferoxamine (DFO) and radiolabeled with the positron-emitting isotope zirconium-89 (89Zr). As a macromolecular tracer, 89Zr-DFO-HSA is designed to exploit the enhanced permeability and retention (EPR) effect in solid tumors, allowing for the noninvasive visualization and quantification of macromolecular accumulation and vascular permeability. It has been evaluated in preclinical mouse xenograft models and the chorioallantoic membrane (CAM) model to study tumor perfusion, vascular barrier defects, and the biodistribution of albumin-based drug delivery systems.
- Other names
- 89Zr-desferrioxamine-HSA89Zr-labeled HSA89Zr-labeled human serum albumin[89Zr]Zr-DFO-HSAzirconium-89-labeled human serum albuminzirconium89-labeled human serum albuminzirconium 89-labeled human serum albumin
Beyond the preview
Go deeper on 89Zr-DFO-HSA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-HSA.